Oklo (OKLO) Stock Prediction: $72 Bull Case vs $22 Bear Case

The loudest Oklo stock prediction in circulation this month is a eulogy: a pre-revenue reactor developer down 77% from its peak must be running out of road. The filings say the reverse. Oklo closed at $39.88 on 10 September 2026, yet on 30 June it held $3,006.3 million in cash, cash equivalents and marketable debt securities, according to its quarterly report filed on 7 August. That is roughly $16.16 of cash behind every share. The stock did not collapse because the money ran out. It collapsed because the money came in, at prices the market no longer pays, and because the first commercial Aurora powerhouse is still a 2028 target rather than a plant. Our 12-month view puts a $72 bull case against a $22 bear case, with a $45 base.

Here is the number no bullish or bearish take on OKLO stock is quoting. In the first half of 2026 Oklo issued 23,088,406 new shares through its at-the-market programmes at an average net price of $81.44, raising $1.88 billion gross. The Street’s average 12-month target today is $79.88. In other words, the analyst consensus is not really a forecast; it is almost exactly the price at which Oklo itself chose to issue stock six months ago. Strip out the cash and the market is valuing the reactor, fuel and isotope business at about $23.70 a share, or roughly $4.4 billion of enterprise value. Having tracked Oklo’s filings since its 2024 listing, I read that as the cleanest way to frame the debate: the question is no longer whether Oklo survives, but what the non-cash business is worth once dilution stops doing the talking.

Key facts

• OKLO closed at $39.88 on 10 September 2026, down 6.32% on the day and 77.1% below its $174.14 highest close of 14 October 2025 — stockanalysis.com, 10 Sep 2026
• Cash, cash equivalents and marketable debt securities stood at $3,006.3 million on 30 June 2026 — Oklo Form 10-Q, 7 Aug 2026
• Shares outstanding rose to 186,017,650 on 4 August 2026 from 160,514,103 on 31 December 2025, a 15.9% increase in seven months — Oklo Form 10-Q, 7 Aug 2026
• A new $1.0 billion at-the-market equity programme was signed on 13 May 2026, after the prior $1.5 billion programme was fully used — Oklo Form 8-K, 13 May 2026
• Second-quarter revenue was $1.21 million, the first in the company’s history, against a net loss of $48.5 million, or $0.28 a share — Oklo Form 10-Q, 7 Aug 2026
• The Groves Isotope Test Reactor in Lockhart, Texas reached first criticality on 5 August 2026 under the DOE Reactor Pilot Program — DOE Office of Nuclear Energy, Aug 2026
• The average 12-month analyst target is $79.88 across 25 analysts polled by S&P Global, with a range of $14 to $130 — stockanalysis.com forecast page, 11 Sep 2026

Why Oklo stock fell 77%: a cohort unwind, a share-count problem and a long runway

Start with the chart and the peer group, because the move is less idiosyncratic than it looks. Oklo’s highest close in the past year was $174.14 on 14 October 2025. NuScale Power made its own peak close a day later, and the pre-revenue advanced-nuclear cohort has been deflating together ever since. On stockanalysis.com closing data for 10 September, NuScale sits 80.9% below its highest close and NANO Nuclear 69.3% below. Oklo, at 77.1% down, is in the middle of that pack, not at the bottom of it. The operators with existing reactors and cash flows, Constellation Energy and Cameco, are down 29.2% and 27.3% respectively from their own peaks. The market has drawn a hard line between nuclear that generates today and nuclear that generates in 2028 or later.

The second driver is Oklo’s own share issuance. The company used the rally well. Under its 2025 at-the-market programme it issued 12,376,352 shares in the first quarter of 2026 at an average net $96.95. When that $1.5 billion facility was exhausted, the company signed a new $1.0 billion agreement with a ten-bank syndicate including Goldman Sachs and J.P. Morgan on 13 May. By 30 June a further 10,712,054 shares had been placed at an average net $63.51, for $680.4 million gross. That leaves roughly $319.6 million of capacity on the current programme, based on the 10-Q’s own gross-proceeds figure. The treasury is stronger for it; per-share ownership is not. Against the 147,609,194 shares reported on the cover of the August 2025 10-Q, the count has risen by 26%.

The third driver is time. The 10-Q is candid about it: “We have an ambitious target of deploying our first powerhouse in 2028 amidst a range of supply chain, construction, macroeconomic, and design complexities.” For a stock priced on the scale of its customer pipeline, every quarter without a firm construction milestone at the Idaho site is a quarter in which the discount rate does the damage. A 12 gigawatt master power agreement with Switch, signed in December 2024, and a 1.2 gigawatt prepayment framework with Meta Platforms for Pike County, Ohio, signed on 5 January 2026, are large headline numbers. Neither yet produces power revenue.

Insider selling has added to the drift, although it explains tone rather than direction. The Form 4 filings of co-founders Jacob DeWitte, the chief executive, and Caroline Cochran, the chief operating officer, report identical transactions under Rule 10b5-1 trading plans: 200,000 shares on 1 June at a weighted average of $68.29, 200,000 on 1 July at $52.93, 120,000 on 3 August at $40.87 and 120,000 on 1 September at $38.59. Chief financial officer Craig Bealmear disposed of 16,430 shares on 1 and 2 September at an average $38.76, also under a 10b5-1 plan. Pre-arranged plans are routine for founders. The optics of a steady monthly cadence into a falling tape are not helpful, and social chatter has picked up on them.

How Oklo is responding: a reactor that went critical, DOE approvals and a fuel plan

The company’s answer to “when does anything get built” arrived on 5 August. The Groves Isotope Test Reactor, a low-power unit in Lockhart, Texas, achieved first criticality under the Department of Energy’s Reactor Pilot Program. DOE’s Office of Nuclear Energy called it the fifth DOE-authorised advanced reactor to achieve criticality this summer, and Oklo’s 10-Q says it was the first under the pilot programme to do so on private land. “Reaching criticality in less than a year is an incredible milestone for our team,” said Jacob DeWitte, co-founder and CEO at Oklo. “Thanks to President Trump’s precedent-setting directive to create the Reactor Pilot Program, Oklo’s Groves Isotope Test Reactor is part of the revival of America’s nuclear energy industry,” said Ted Garrish, Assistant Secretary for Nuclear Energy at the U.S. Department of Energy.

Groves matters less for its output than for what it proves about execution. According to the 10-Q, the project moved through DOE approval of its Nuclear Safety Design Agreement on 17 March, its Preliminary Documented Safety Analysis on 27 May and its Documented Safety Analysis on 30 June before loading fuel. That is a full authorisation cycle completed inside a year, on a site Oklo developed itself. The market’s reaction was brief: the stock closed at $47.01 on 11 August and was back at $39.88 a month later.

On the flagship Aurora powerhouse at Idaho National Laboratory, the milestones are also coming from DOE rather than the Nuclear Regulatory Commission. DOE approved the Nuclear Safety Design Agreement for Aurora-INL early in 2026 and the Preliminary Documented Safety Analysis on 11 June 2026, which Oklo describes as two of five steps in the DOE pathway to operation. Kiewit has been selected as lead constructor. A Notice of Intent to Award from the Defense Logistics Agency-Energy tentatively selects Oklo to supply at least 5 MWe of power and heat to Eielson Air Force Base in Alaska.

Fuel remains the constraint the company talks about most. Oklo holds a DOE award of five metric tons of high-assay low-enriched uranium (HALEU) recovered from EBR-II fuel for the first Idaho unit. In June it signed a letter of intent with Centrus Energy for domestically produced HALEU sufficient for up to five Aurora powerhouses, with deliveries expected to begin in 2029; pricing, volume and prepayment terms remain subject to a definitive agreement. In May Oklo was selected for advanced negotiations under DOE’s Surplus Plutonium Utilization Program. The company also appointed five executive officers effective 27 July, according to an 8-K filed on 28 July, among them chief product officer Alexandra Renner, a former NRC reactor inspector who joined Oklo in 2016.

OKLO market data: the chart, the peers and what the cash is worth

The chart shows two distinct legs. The first, from October 2025 into April 2026, was the unwind of the AI-power narrative, when the stock fell from $174 to below $50. The second began after a brief spring rebound peaked at a $79.62 close on 6 May; the stock has ground lower since the new equity programme was signed a week later, on 13 May. The 12-month low close was $36.84 on 29 July. Spot is 8% above it. Pre-market indications on 11 September were around $40, but this analysis anchors on the $39.88 regular-session close.

Source: stockanalysis.com daily closes, computed by FinanceFeeds on 11 Sep 2026.

Now the balance sheet. At $39.88 and 186.0 million shares, Oklo’s market capitalisation is about $7.42 billion. Subtract $3.01 billion of cash and securities and the enterprise value is roughly $4.41 billion. The first half’s cash consumption was modest by comparison: $65.5 million used in operations and $126.9 million spent on property, plant and equipment, about $192 million in total. Management states that existing cash will fund operations for at least a year from the filing date. At the first-half pace, the pile covers several years of spending before construction capex steps up.

The comparison with other developers is useful here. FinanceFeeds’ NuScale price prediction and the X-energy bull and bear case both run into the same question of how long investors will fund a reactor before it sells electricity. Oklo’s distinction is that it has already raised the money for the next phase.

The regulatory and structural tension: DOE speed, NRC uncertainty and the dilution overhang

The fastest part of Oklo’s story is also its most fragile. Groves and Aurora-INL are both advancing under DOE authorisation, the pathway created for the Reactor Pilot Program. It is quicker than the NRC route. But the commercial fleet that justifies a multi-billion-dollar valuation, including the Meta campus in Ohio and the Switch framework, will need NRC licensing. On that front, the 10-Q describes a Phase I pre-application readiness assessment with the NRC completed in July 2025, which found no significant gaps, and states plainly: “It is uncertain when, if at all, we will obtain NRC approvals for the design, construction, and operation of” its powerhouses. The same filing notes that the planned Tennessee fuel recycling facility is in pre-application engagement with NRC staff. A pilot programme win does not transfer automatically into a commercial licence.

Fuel is the second tension. Oklo’s own filing says the cost of fuel sources, HALEU included, “has increased significantly in recent years”. The Centrus arrangement is a letter of intent with deliveries from 2029, and the plutonium route depends on DOE authorisation, safeguards and cost-recovery terms that are not yet fixed. The operators in our energy stocks roundup and the uranium supplier in our Cameco stock prediction sit on the other side of that trade, which is why they have held up while the developers have not.

The third tension is structural and specific to OKLO stock: the equity programme. With about $319.6 million left on the current facility at 30 June, fully drawing it at $40 would mean roughly 8 million new shares, about 4.3% dilution. That is manageable. The larger risk is a new, bigger programme signed at depressed prices to fund Aurora construction and fuel prepayments. Oklo issued aggressively while its stock was expensive, which was sensible; the market now reads every new filing as fresh supply.

Oklo stock prediction: base, bull and bear OKLO price targets for the next 12 months

All levels are 12-month views from the $39.88 close of 10 September 2026. They are built on cash per share, the value the market is implicitly assigning to the operating business, and the licensing milestones that could re-rate it.

Base case, $45 (50%). The stock stabilises and grinds modestly higher as the cash floor limits the downside and the remaining ATM capacity is used sparingly. Aurora-INL progresses through the later DOE steps, Groves begins producing operating data, and the Centrus and Meta arrangements move towards definitive terms without a firm NRC date for the commercial fleet. The market continues to value the non-cash business at around $5 billion. Probability-weighted across all three scenarios, the expected value is roughly $46.

Bull case, $72 (25%). This is a return to just below the $79.62 spring rebound close of 6 May and a little above the $63.51 average net price at which Oklo issued stock in the second quarter. It requires a visible acceleration: DOE approval of the final Documented Safety Analysis for Aurora-INL, construction milestones with Kiewit on schedule for 2028, a definitive Centrus HALEU supply agreement, and a binding step on the Meta campus. Even then, $72 sits below the $79.88 Street average and well below the $81.44 average issuance price of the first half. I do not assume the 2025 multiple returns.

Bear case, $22 (25%). Aurora-INL slips beyond 2028, fuel costs rise, and Oklo signs a new, larger equity programme at depressed prices. On our estimate, cash per share would fall from $16.16 today towards $13 to $14 over the next year as spending steps up and new shares are issued. At $22 the market would still value the operating business at about $8 a share, under $2 billion.

Invalidation and what would change my mind. The bear case is invalidated by a definitive, priced HALEU supply contract and a firm NRC docketing date for the first commercial licence application. The bull case is invalidated by a close below $36.61, the 52-week intraday low, alongside a new equity programme larger than $1 billion. I would move the base case up if the Meta prepayment turns into disclosed cash on the balance sheet. I would move it down if the next 10-Q shows operating cash use plus capex running above $500 million annualised without a matching construction milestone.

FAQ

What is the Oklo stock prediction for the next 12 months?

FinanceFeeds sets a $45 base case for OKLO, 12.8% above the $39.88 close of 10 September 2026, with a 50% probability. The bull case is $72 (+80.5%, 25% probability) on DOE and fuel milestones; the bear case is $22 (-44.8%, 25%) on delays and further dilution. These are analytical scenarios, not trading instructions.

Why did Oklo stock fall so much in 2026?

Three forces combined. The pre-revenue nuclear cohort unwound from its October 2025 peak, with NuScale and NANO Nuclear falling by similar margins. Oklo issued 23.1 million new shares in the first half of 2026 at far higher prices than today. And the first Aurora powerhouse remains a 2028 target, so near-term revenue is minimal.

How much cash does Oklo have?

Oklo reported $3,006.3 million in cash, cash equivalents and marketable debt securities at 30 June 2026 in its 10-Q filed on 7 August. With 186.0 million shares outstanding on 4 August, that is about $16.16 per share. First-half operating cash use was $65.5 million plus $126.9 million of capital spending.

What is the average OKLO price target from analysts?

The average 12-month OKLO price target is $79.88 from 25 analysts polled by S&P Global, as shown on stockanalysis.com on 11 September 2026. Estimates range from $14 to $130. In the August tally, 15 analysts sat in the two most positive rating tiers, nine were neutral and one was negative.

Does Oklo have an NRC licence for its Aurora reactor?

Not for commercial operation. The first Aurora unit at Idaho National Laboratory is advancing under the DOE authorisation pathway, which approved its Preliminary Documented Safety Analysis on 11 June 2026. Oklo’s 10-Q says it is uncertain when, if at all, it will obtain NRC approvals for its commercial powerhouses.

Disclaimer

This article is analysis for information purposes only and is not investment advice, a recommendation or an offer to deal in any security. Price levels and probabilities are FinanceFeeds scenarios and may prove wrong. Shares in pre-revenue companies are highly volatile; capital is at risk and past performance is not a reliable indicator of future results.